Actavis Inc (ACT) 272.28 $ACT
Celgene Says Q4 Earnings Beat, Sees Currency Impact
at Investor's Business Daily - Mon Jan 12, 12:12PM CST
Big cap biotech Celgene (CELG) provided a preliminary fourth-quarter earnings report Monday that topped estimates but warned of foreign exchange currency impacts for the year ahead. Results were presented prior to its presentation early Monday at the...
AGN: 219.58 (+4.18), VRX: 155.50 (+1.92), ACT: 272.28 (+3.60), CELG: 117.00 (+3.33)
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector
Cerebro1 - at Seeking Alpha - Mon Jan 12, 11:10AM CST
AGN: 219.58 (+4.18), VRTX: 118.31 (-3.90), ACT: 272.28 (+3.60), XLV: 70.24 (+0.03), CELG: 117.00 (+3.33)
FTC grants early termination of HSR waiting period for Actavis/Allergan deal
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:34AM CST
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60)
Actavis reports February 18
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 7:56AM CST
ACT: 272.28 (+3.60)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 104.58 (-0.36), SQNM: 3.75 (-0.02), ACT: 272.28 (+3.60), VVUS: 3.30 (+0.09), CVD: 105.92 (-0.09)
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance
PR Newswire - Mon Jan 12, 7:30AM CST
Actavis plc (NYSE: ACT), in advance of the start of the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a preliminary review of 2014 fourth quarter results it expects non-GAAP earnings per share to exceed Wall Street consensus estimates by 10 percent to 15 percent. Actavis' preliminary results remain subject to finalization by its management and review by its outside independent accountants. The company plans to report final results for the fourth quarter and full year 2014 on February 18, 2015.
ACT: 272.28 (+3.60), JPM: 58.83 (-0.51)
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings
Business Wire - Mon Jan 12, 7:02AM CST
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Actavis' pending acquisition of Allergan.
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
Four Best Gains In IBD 50: Nothing To Do With Oil
at Investor's Business Daily - Fri Jan 09, 5:35PM CST
The market's resumed uptrend seemed more steer than bull this past week, but the IBD 50 list ended Friday with a healthy offering of stocks in bases, finding support and spiking to new highs. The week's prevailing influence, once again, was a...
AMBA: 61.90 (+0.07), ACT: 272.28 (+3.60), AKRX: 40.51 (-0.21), NXPI: 80.35 (+0.03), ULTA: 129.84 (-1.73), JD: 24.11 (-0.83), SHW: 271.10 (-3.32), MANH: 42.87 (-0.65), AVGO: 103.16 (-1.73), BITA: 74.04 (-15.07)
Is Gilead Sciences Inc. Now a Takeover Target?
George Budwell, The Motley Fool - Motley Fool - Fri Jan 09, 7:09AM CST
The pharmaceutical industry underwent a widespread consolidation last year, triggered by record profits for some mid- to large-cap companies like Actavis , as well as falling revenues for big pharmas like Merck & Co. As these conditions are...
JNJ: 104.58 (-0.36), ACT: 272.28 (+3.60), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), NVS: 95.48 (-0.64)
Cramer's Mad Money - Top 10 Performers Of The S&P 500 For 2014 (1/8/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Jan 09, 4:33AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday January 8. Top 10 S&P Performers for 2014: Southwest Airlines (NYSE: LUV ), Electronic Arts (NASDAQ: EA ), Edwards Lifesciences (NYSE: EW ), Allergan...
KO: 42.64 (-0.39), MNK: 102.46 (-1.11), ACT: 272.28 (+3.60), KR: 66.00 (+0.16), HDP: 29.20 (+2.23), EA: 47.06 (-0.45), GMCR: 133.91 (-3.80), DAL: 46.06 (-0.82), IP: 53.21 (+0.15), EW: 135.29 (+2.13), HPQ: 39.92 (-0.75), LUV: 40.25 (-0.54), AGN: 219.58 (+4.18), TTWO: 27.87 (unch), RCL: 83.26 (-0.66), LYB: 76.15 (-2.83), DD: 74.41 (+0.91), CVX: 105.88 (-2.33), AAPL: 109.25 (-2.76), PPG: 226.25 (-0.72), AVGO: 103.16 (-1.73), CRM: 57.73 (-0.43)
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
at The Street - Thu Jan 08, 7:23PM CST
Cramer says the markets suffered from a 'depressive mood disorder' but those investors who obeyed their rational brains made a ton of mad money.
CXO: 95.08 (-4.34), CYTK: 7.80 (unch), MNST: 111.96 (-5.08), LMT: 194.47 (-0.55), ACT: 272.28 (+3.60), EA: 47.06 (-0.45), OMED: 25.00 (-1.14), UTX: 114.45 (+0.43), DAL: 46.06 (-0.82), GMCR: 133.91 (-3.80), SKX: 60.48 (+1.14), ED: 66.90 (-0.23), JBLU: 14.55 (+0.17), INTC: 36.60 (-0.16), LUV: 40.25 (-0.54), AGN: 219.58 (+4.18), RCL: 83.26 (-0.66), SAVE: 69.64 (-3.47), AAL: 49.58 (-2.44), AAPL: 109.25 (-2.76), KING: 13.74 (+0.16), MNK: 102.46 (-1.11), CY: 14.99 (-0.05), ANW: 14.54 (+0.28), SE: 33.70 (+0.03), KR: 66.00 (+0.16), SWKS: 72.32 (-1.76), HES: 68.43 (-2.69), BLOX: 20.86 (-0.07), EW: 135.29 (+2.13), DIS: 94.46 (+0.21), SN: 8.56 (-0.32), BAC: 16.68 (-0.30), BMY: 62.18 (+1.86), UA: 67.13 (-0.52), TTWO: 27.87 (unch), PM: 83.05 (+0.33), CG: 25.85 (-0.73), ISIS: 73.34 (+1.08), CVX: 105.88 (-2.33), AVGO: 103.16 (-1.73), JCI: 46.09 (-0.67)
Four Hot Growth Stocks To Put On Your Watch List
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
With the market staging a follow-through on Thursday, it's OK for investors to start buying leading stocks again. A number of top-rated stocks in the Spotlight screen are either forming bases or getting support at their 10-week lines, giving...
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60), DPZ: 102.12 (+1.62), NXPI: 80.35 (+0.03), AVGO: 103.16 (-1.73)
Adamas earns milestone from Actavis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:19PM CST
ACT: 272.28 (+3.60), ADMS: 16.97 (+0.11)
Great News! An Exciting New Drug for Depression May Be on the Way
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 08, 11:04AM CST
Depression is so common that experts refer to it as the "common cold" of mental health. But treatment options are still coming up short for the up to 16 million Americans who suffer clinical depression each year, even though antidepressants are one...
ACT: 272.28 (+3.60), PFE: 32.77 (+0.12), LLY: 69.42 (-0.51), ALKS: 68.61 (+3.47)
Is AbbVie Inc. Ripe for a Buyout?
George Budwell, The Motley Fool - Motley Fool - Thu Jan 08, 9:09AM CST
The pharmaceutical industry is undergoing an unprecedented level of consolidation right now, triggered by the loss of patent protection for numerous top-selling drugs in recent years, a desire to lower effective tax rates, and the approval of a host...
ESRX: 83.08 (-1.82), ACT: 272.28 (+3.60), GILD: 101.21 (-1.00), SHPG: 209.10 (-8.39), AZN: 70.79 (+1.35), PFE: 32.77 (+0.12), ABBV: 65.76 (-0.02)
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:35PM CST
Actavis plc (ACT) confirmed that the U.S. Court of Appeals for the Second Circuit has granted the company's motion to expedite its appeal of a lower court ruling in Dec 2014, whereby Actavis was required to continue distribution of Namenda immediate-release (IR) tablets.
PGNX: 6.80 (-0.29), ACT: 272.28 (+3.60), SUPN: 8.71 (-0.05), MYL: 55.27 (-0.57)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 6.80 (-0.29), ACT: 272.28 (+3.60), KBIO: 0.50 (unch), SUPN: 8.71 (-0.05)
10 Stocks Every Millennial Should Add to Their Portfolio Right Now
at The Street - Wed Jan 07, 10:37AM CST
Trained to chase the upside and ride the downside, millennials have had a rocky real-world education when it comes to investing. Here are 10 stocks they all should own.
ACT: 272.28 (+3.60), EBAY: 55.20 (-0.43), SCTY: 49.32 (-0.30), FUEL: 14.95 (-0.60), XOM: 90.33 (-1.77), BAC: 16.68 (-0.30), KATE: 28.17 (+0.01), GOOG: 492.55 (-3.62), AAPL: 109.25 (-2.76), K: 65.48 (-0.95)
Celgene Says Q4 Earnings Beat, Sees Currency Impact
at Investor's Business Daily - Mon Jan 12, 12:12PM CST
Big cap biotech Celgene (CELG) provided a preliminary fourth-quarter earnings report Monday that topped estimates but warned of foreign exchange currency impacts for the year ahead. Results were presented prior to its presentation early Monday at the...
AGN: 219.58 (+4.18), VRX: 155.50 (+1.92), ACT: 272.28 (+3.60), CELG: 117.00 (+3.33)
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector
Cerebro1 - at Seeking Alpha - Mon Jan 12, 11:10AM CST
AGN: 219.58 (+4.18), VRTX: 118.31 (-3.90), ACT: 272.28 (+3.60), XLV: 70.24 (+0.03), CELG: 117.00 (+3.33)
FTC grants early termination of HSR waiting period for Actavis/Allergan deal
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:34AM CST
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60)
Actavis reports February 18
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 7:56AM CST
ACT: 272.28 (+3.60)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 104.58 (-0.36), SQNM: 3.75 (-0.02), ACT: 272.28 (+3.60), VVUS: 3.30 (+0.09), CVD: 105.92 (-0.09)
Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance
PR Newswire - Mon Jan 12, 7:30AM CST
Actavis plc (NYSE: ACT), in advance of the start of the 33rd Annual J.P. Morgan Healthcare Conference, today announced that based on a preliminary review of 2014 fourth quarter results it expects non-GAAP earnings per share to exceed Wall Street consensus estimates by 10 percent to 15 percent. Actavis' preliminary results remain subject to finalization by its management and review by its outside independent accountants. The company plans to report final results for the fourth quarter and full year 2014 on February 18, 2015.
ACT: 272.28 (+3.60), JPM: 58.83 (-0.51)
Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings
Business Wire - Mon Jan 12, 7:02AM CST
Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Actavis' pending acquisition of Allergan.
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
Four Best Gains In IBD 50: Nothing To Do With Oil
at Investor's Business Daily - Fri Jan 09, 5:35PM CST
The market's resumed uptrend seemed more steer than bull this past week, but the IBD 50 list ended Friday with a healthy offering of stocks in bases, finding support and spiking to new highs. The week's prevailing influence, once again, was a...
AMBA: 61.90 (+0.07), ACT: 272.28 (+3.60), AKRX: 40.51 (-0.21), NXPI: 80.35 (+0.03), ULTA: 129.84 (-1.73), JD: 24.11 (-0.83), SHW: 271.10 (-3.32), MANH: 42.87 (-0.65), AVGO: 103.16 (-1.73), BITA: 74.04 (-15.07)
Is Gilead Sciences Inc. Now a Takeover Target?
George Budwell, The Motley Fool - Motley Fool - Fri Jan 09, 7:09AM CST
The pharmaceutical industry underwent a widespread consolidation last year, triggered by record profits for some mid- to large-cap companies like Actavis , as well as falling revenues for big pharmas like Merck & Co. As these conditions are...
JNJ: 104.58 (-0.36), ACT: 272.28 (+3.60), GILD: 101.21 (-1.00), PFE: 32.77 (+0.12), MRK: 62.30 (-0.26), CVS: 97.20 (-0.72), ABBV: 65.76 (-0.02), NVS: 95.48 (-0.64)
Cramer's Mad Money - Top 10 Performers Of The S&P 500 For 2014 (1/8/15)
SA Editor Miriam Metzinger - at Seeking Alpha - Fri Jan 09, 4:33AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday January 8. Top 10 S&P Performers for 2014: Southwest Airlines (NYSE: LUV ), Electronic Arts (NASDAQ: EA ), Edwards Lifesciences (NYSE: EW ), Allergan...
KO: 42.64 (-0.39), MNK: 102.46 (-1.11), ACT: 272.28 (+3.60), KR: 66.00 (+0.16), HDP: 29.20 (+2.23), EA: 47.06 (-0.45), GMCR: 133.91 (-3.80), DAL: 46.06 (-0.82), IP: 53.21 (+0.15), EW: 135.29 (+2.13), HPQ: 39.92 (-0.75), LUV: 40.25 (-0.54), AGN: 219.58 (+4.18), TTWO: 27.87 (unch), RCL: 83.26 (-0.66), LYB: 76.15 (-2.83), DD: 74.41 (+0.91), CVX: 105.88 (-2.33), AAPL: 109.25 (-2.76), PPG: 226.25 (-0.72), AVGO: 103.16 (-1.73), CRM: 57.73 (-0.43)
Jim Cramer's 'Mad Money' Recap: You'll Make More Money Buying Into Panic
at The Street - Thu Jan 08, 7:23PM CST
Cramer says the markets suffered from a 'depressive mood disorder' but those investors who obeyed their rational brains made a ton of mad money.
CXO: 95.08 (-4.34), CYTK: 7.80 (unch), MNST: 111.96 (-5.08), LMT: 194.47 (-0.55), ACT: 272.28 (+3.60), EA: 47.06 (-0.45), OMED: 25.00 (-1.14), UTX: 114.45 (+0.43), DAL: 46.06 (-0.82), GMCR: 133.91 (-3.80), SKX: 60.48 (+1.14), ED: 66.90 (-0.23), JBLU: 14.55 (+0.17), INTC: 36.60 (-0.16), LUV: 40.25 (-0.54), AGN: 219.58 (+4.18), RCL: 83.26 (-0.66), SAVE: 69.64 (-3.47), AAL: 49.58 (-2.44), AAPL: 109.25 (-2.76), KING: 13.74 (+0.16), MNK: 102.46 (-1.11), CY: 14.99 (-0.05), ANW: 14.54 (+0.28), SE: 33.70 (+0.03), KR: 66.00 (+0.16), SWKS: 72.32 (-1.76), HES: 68.43 (-2.69), BLOX: 20.86 (-0.07), EW: 135.29 (+2.13), DIS: 94.46 (+0.21), SN: 8.56 (-0.32), BAC: 16.68 (-0.30), BMY: 62.18 (+1.86), UA: 67.13 (-0.52), TTWO: 27.87 (unch), PM: 83.05 (+0.33), CG: 25.85 (-0.73), ISIS: 73.34 (+1.08), CVX: 105.88 (-2.33), AVGO: 103.16 (-1.73), JCI: 46.09 (-0.67)
Four Hot Growth Stocks To Put On Your Watch List
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
With the market staging a follow-through on Thursday, it's OK for investors to start buying leading stocks again. A number of top-rated stocks in the Spotlight screen are either forming bases or getting support at their 10-week lines, giving...
AGN: 219.58 (+4.18), ACT: 272.28 (+3.60), DPZ: 102.12 (+1.62), NXPI: 80.35 (+0.03), AVGO: 103.16 (-1.73)
Adamas earns milestone from Actavis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:19PM CST
ACT: 272.28 (+3.60), ADMS: 16.97 (+0.11)
Great News! An Exciting New Drug for Depression May Be on the Way
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 08, 11:04AM CST
Depression is so common that experts refer to it as the "common cold" of mental health. But treatment options are still coming up short for the up to 16 million Americans who suffer clinical depression each year, even though antidepressants are one...
ACT: 272.28 (+3.60), PFE: 32.77 (+0.12), LLY: 69.42 (-0.51), ALKS: 68.61 (+3.47)
Is AbbVie Inc. Ripe for a Buyout?
George Budwell, The Motley Fool - Motley Fool - Thu Jan 08, 9:09AM CST
The pharmaceutical industry is undergoing an unprecedented level of consolidation right now, triggered by the loss of patent protection for numerous top-selling drugs in recent years, a desire to lower effective tax rates, and the approval of a host...
ESRX: 83.08 (-1.82), ACT: 272.28 (+3.60), GILD: 101.21 (-1.00), SHPG: 209.10 (-8.39), AZN: 70.79 (+1.35), PFE: 32.77 (+0.12), ABBV: 65.76 (-0.02)
Actavis' Appeal Case for Namenda Gets Accelerated Hearing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 3:35PM CST
Actavis plc (ACT) confirmed that the U.S. Court of Appeals for the Second Circuit has granted the company's motion to expedite its appeal of a lower court ruling in Dec 2014, whereby Actavis was required to continue distribution of Namenda immediate-release (IR) tablets.
PGNX: 6.80 (-0.29), ACT: 272.28 (+3.60), SUPN: 8.71 (-0.05), MYL: 55.27 (-0.57)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 6.80 (-0.29), ACT: 272.28 (+3.60), KBIO: 0.50 (unch), SUPN: 8.71 (-0.05)
10 Stocks Every Millennial Should Add to Their Portfolio Right Now
at The Street - Wed Jan 07, 10:37AM CST
Trained to chase the upside and ride the downside, millennials have had a rocky real-world education when it comes to investing. Here are 10 stocks they all should own.
ACT: 272.28 (+3.60), EBAY: 55.20 (-0.43), SCTY: 49.32 (-0.30), FUEL: 14.95 (-0.60), XOM: 90.33 (-1.77), BAC: 16.68 (-0.30), KATE: 28.17 (+0.01), GOOG: 492.55 (-3.62), AAPL: 109.25 (-2.76), K: 65.48 (-0.95)
